Phaseline

Companies › Dendreon

Dendreon: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 3 Phase 2, 2 Phase 1; Oncology; next expected readout Dec 2031.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sipuleucel-T
Prostatic acid phosphatase binding agent
ACP3Phase 2Metastatic Castration-Resistant Prostate Cancer (mCRPC); Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Metastatic Castration-Resistant Prostate AdenocarcinomaDec 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05751941Sipuleucel-TPhase 2Prostate CancerOncologyDec 2026
NCT06100705Sipuleucel-TPhase 2Metastatic Castration-resistant Prostate CancerOncologyDec 2027
NCT05806814Sipuleucel-TPhase 1Metastatic Castration-Resistant Prostate Cancer (mCRPC)OncologyMay 2028
NCT07219147Sipuleucel-TPhase 1Metastatic Castration-Resistant Prostate AdenocarcinomaOncologyJul 2028
NCT06134232Sipuleucel-TPhase 2Metastatic Castration-Resistant Prostate Cancer (mCRPC)OncologyDec 2031

Targets

ACP3 (1)

Companies with the same targets

–

Companies built like this

CNBG-Virogin Biotech (Shanghai) Stella Pharma Hangzhou Converd Abscint NV/SA Beijing Gene Key Life Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.